TickerGuard
Buy Day today: Neutral (59) Mixed market breadth · major macro event coming up
ONC

BeiGene, Ltd.

Healthcare · Biotechnology · listed since 2016

356.00$ -0.8% vs. previous close Closing price · As of: Aug 13, 2026
🔔 Watch stock
Add to watchlist

Stock Watch

Stock Watch will tell you what changes at BeiGene, Ltd..

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Price history

Chart

Interactive price chart (TradingView).

52-week range: 260.30 $ to 377.50 $ · Last price: 356.00 $ (As of: August 13, 2026)

Key figures

Key figures at a glance

Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.

Basics

Market Cap ?The value of the entire company on the market: share price times total shares outstanding. 40.3$B
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. –
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. –
Beta ?Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market. –

Performance

Perf. 1M ?Price performance over the last month. 18.20%
Perf. 3M ?Price performance over the last 3 months. 15.60%
Perf. 6M ?Price performance over the last 6 months. 3.00%
YTD Performance (%) ?Price performance since the start of the year (Year to Date). 18.25%
52-Week-High Distance ?How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high. -4.8%
Perf. 1Y ?Price performance over the last 12 months. 15.77%
Perf. 3Y ?Price performance over the last 3 years. 80.09%
Perf. 5Y ?Price performance over the last 5 years. 28.90%
Perf. 10Y ?Price performance over the last 10 years. 1,164.69%
Perf. Since Inception ?Price performance since the first available trading day (02/03/2016) — with a complete history, that is since the IPO. 1,157.10%

Technical Indicators

MA 38 Days ?Moving average of the last 38 trading days: the smoothed price path. A price above it signals short-term strength. 313.60$
MA 50 Days ?Moving average of the last 50 trading days — the most widely watched medium-term trend line. 302.70$
MA 200 Days ?Moving average of the last 200 trading days — the dividing line between a long-term uptrend and downtrend. 315.20$
RSI (14) ?Relative Strength Index over 14 days, scale 0 to 100: above 70 counts as overbought, below 30 as oversold. A hint on timing, not a verdict on the company. 73.2
Volatility 30 Days ?Price swings over the last 30 trading days, annualized. The higher the value, the more the price fluctuates. 29.3%
Volatility 250 Days ?Price swings over the last 250 trading days (roughly one market year), annualized. 39.5%

Calculated from the price history · as of 08/14/2026

Valuation

P/E ?Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E. 63.6
Forward P/E ?P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future. –
PEG ?P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey. –
P/B ?Price-to-book ratio: market value relative to book equity. 7.8
P/S ?Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable. 6.6
EV/EBITDA ?Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero. –
Price/FCF ?Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up. 32.4

Profitability

Gross Margin ?Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power. –
EBIT Margin ?EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes. 19.1%
Net Margin ?Net margin: what's left of sales as profit after ALL costs, interest, and taxes. –
Return on Equity ?Return on equity: how much profit does the company generate per year on shareholders' equity? 14.7%
Return on Assets ?Return on assets: how much profit the company generates from its total assets (equity and debt combined). –

Balance Sheet & Safety

Equity Ratio ?Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet. 53.3%
Debt/Equity ?Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity. 0.3
Altman Z″ ?Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks. fortress balance sheet 6.43
Piotroski ?Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag. 7 out of 9

Growth

Sales Growth Last Quarter ?Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY). 29.60%
EPS Growth Last Quarter ?Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY). 166.70%
Sales Growth (Year) ?Sales growth in the last fiscal year versus the year before. 40.23%
Forward Sales Growth ?Sales growth analysts expect over the next 12 months — an estimate, not a guarantee. -67.21%
Forward EPS Growth ?Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee. 197.70%

Dividend

No dividend data is available for this stock yet.

Quality & Screener

Stage ?Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line. –
RS Rating ?Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks. –
EPS Rating ?Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth. –
Fundamental Rating ?Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below. A (77 out of 100)

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Comparison

Industry comparison

The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.

Industry: Biotechnology

Industry comparison
Company Market cap ($B) P/E EV/EBITDA Gross Margin % EBIT Margin % Sales Growth (Year) % Perf. 1Y %
BeiGene, Ltd. ONC 40.3 63.6 – – 19.1 40.2 15.8
Vertex Pharmaceuticals Inc VRTX 130.6 31.4 23.3 54.4 38.1 9.6 30.4
Regeneron Pharmaceuticals Inc REGN 83.7 20.1 12.7 44.5 20.7 1.0 44.3
argenx NV ARGX 53.3 32.7 – – 32.0 89.6 32.5
Revolution Medicines Inc RVMD 42.0 – -9.7 -151,691.8 0.0 -100.0 460.0
Royalty Pharma Plc RPRX 32.3 31.7 19.7 115.0 100.3 5.1 64.1
Alnylam Pharmaceuticals Inc ALNY 30.1 56.6 23.0 79.7 23.0 65.2 -47.5
Insmed Inc INSM 27.4 – -6.0 81.8 -65.5 66.7 2.8
Roivant Sciences Ltd ROIV 25.4 – 0.7 -8,159.0 -14,675.1 -71.6 203.3
Median of companies shown 40.3 32.2 12.7 54.4 20.7 9.6 32.5

Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →

Quarters

Quarterly Figures

Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q3 · 1,001.6 $M Q3 2024: Q4 · 1,127.8 $M Q4 2025: Q1 · 1,117.3 $M Q1 2025: Q2 · 1,315.3 $M Q2 2025: Q3 · 1,412.3 $M Q3 2025: Q4 · 1,498.2 $M Q4 2026: Q1 · 1,513.4 $M Q1 2026: Q2 · 1,705.1 $M Q2

Source: fundamental data

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q3 -1.15 -157.20 1,002 28.20 -12.10 188 55
2024: Q4 -1.43 58.90 1,128 77.80 -13.50 75 -17
2025: Q1 0.01 100.40 1,117 48.60 0.10 44 -72
2025: Q2 0.84 173.00 1,315 41.60 7.20 264 200
2025: Q3 1.09 194.80 1,412 41.00 8.80 403 355
2025: Q4 0.58 140.60 1,498 32.80 4.40 417 131
2026: Q1 1.96 19,500.00 1,513 35.50 15.00 202 161
2026: Q2 2.05 144.00 1,705 29.60 13.90 664 596

What Do These Terms Mean?

EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Compare with other stocks →

Screening

Appears in These Scanners

This stock currently matches 5 of our scanner strategies — each hit links to the scanner.

Growth

Quality & Balance Sheet

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Outlook

Analysts & Price Target

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Consensus Strong Sell 1 = Strong buy … 5 = Strong sell
Analyst Ratings –
Price Target (average) –
Distance to price –

No price target is available for this stock.

Valuation

What is priced in?

Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.

Today’s market value implies roughly 14.3% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).

What is priced in?
Free cash flow (last twelve months) $1.24B
Market cap $40.27B
Free cash flow in year ten $4.72B
Terminal value as a share of market value 61.7%

It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.

A simplified model calculation — not a forecast and not a recommendation.

AI classification

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.

How the Rating Is Built

Growth

Growth Score

Ten checks against the annual reports — each one passed counts a point.

8 of 10 Growth gem
  • Revenue grows by more than 15% a year over three years 55.7%
  • More than 10% revenue growth is expected for the coming year -67.2%
  • Share count grows by less than 3% a year 3.2%
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 57.9%
  • Gross margin at 40% or higher and without meaningful erosion 87.5%
  • Goodwill from acquisitions does not grow faster than revenue 0.0%
  • Net debt below twice EBITDA 2,548 m net cash
  • Operating cash flow covers the profits of the last three years 1,069 m
  • Return on capital at 15% or higher, or up versus two years ago 7.0%
  • Insiders hold at least 10% or are net buyers 17.3%

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Quality check

AAQS

1/10

The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).

  • Sales growth 10Y > 5% –
  • Exp. sales growth 3Y > 5% –
  • EBIT growth 10Y > 5% –
  • Exp. EBIT growth 3Y > 5% –
  • Net debt < 4x EBIT –
  • EBIT positive, 10Y straight –
  • Max. EBIT decline < 50% –
  • Return on equity > 15% –
  • ROCE > 15% –
  • Expected return > 10% –

View stocks with the full AAQS score · Read the methodology at AlleAktien

Source: fundamental data

Insiders

Insider Transactions

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

Insider Transactions
Date Person Role Type Shares Price Value
Aug 12, 2026 Oyler John Chief Executive Officer Sell 14,102 359.12 5,064,252
Aug 12, 2026 Oyler John Chief Executive Officer Sell 20,899 358.41 7,490,448
Aug 12, 2026 Oyler John Chief Executive Officer Sell 15,396 357.63 5,506,147
Aug 12, 2026 Oyler John Chief Executive Officer Sell 2,515 356.43 896,426
Aug 12, 2026 Oyler John Chief Executive Officer Sell 1,980 354.71 702,320
Aug 11, 2026 Oyler John Chief Executive Officer Sell 4 367.00 1,468
Aug 11, 2026 Oyler John Chief Executive Officer Sell 1,200 366.31 439,574
Aug 11, 2026 Oyler John Chief Executive Officer Sell 3,176 365.26 1,160,079
Aug 11, 2026 Oyler John Chief Executive Officer Sell 5,211 364.31 1,898,442
Aug 11, 2026 Oyler John Chief Executive Officer Sell 13,403 363.45 4,871,344

View all insider transactions →

The company

About the Company

BeOne Medicines AG, ein Onkologieunternehmen, befasst sich mit der Entdeckung und Entwicklung verschiedener Behandlungen für Krebspatienten in den Vereinigten Staaten, China, Europa und international. Zu den Produkten des Unternehmens im kommerziellen Stadium zählen BRUKINSA, ein niedermolekularer Hemmer der Bruton-Tyrosinkinase (BTK) zur Behandlung verschiedener Blutkrebsarten; TEVIMBRA, eine Anti-PD-1-Antikörper-Immuntherapie zur Behandlung verschiedener solider Tumoren und Blutkrebsarten; SYLVANT zur Behandlung erwachsener Patienten mit multizentrischer Castleman-Krankheit; BAITUOWEI für Patientinnen mit Brustkrebs in der Prä- und Perimenopause sowie weitere Krebsarten; und PARTRUVIX zur Behandlung verschiedener solider Tumoren. Zu den Produkten im klinischen Stadium zählen Sonrotoclax BGB-11417, ein niedermolekularer Bcl-2-Hemmer; BGB-16673, eine gegen BTK gerichtete chimäre Degradations-Aktivierungsverbindung, die gegen Wildtyp- und mutiertes BTK wirkt; BG-60366, ein EGFR-gerichteter CDAC; BG-89894 (SYH2039), ein MAT2A-Hemmer; BGB-58067, ein MTA-kooperativer PRMT5-Hemmer; BG-T187 und BG-C0902, ein trispezifischer Anti-EGFRxMET-Antikörper; BGB-26808, ein HPK-1-Hemmer; BGB-C354, ein Anti-B7H3-ADC; Zanidatamab, ein bispezifischer HER2-gerichteter Antikörper; BG-C137, ein Anti-FGFR2b-ADC; BGB-53038, ein Pan-KRAS-Hemmer; BGB-B2033, ein bispezifischer Anti-GPC3x4-1BB-Antikörper; BGB-B3227, ein bispezifischer Anti-MUC1xCD16A-Antikörper; BG-C477, ein Anti-CEA-ADC; BGB-43395, ein CDK4-Hemmer; BG-68501, ein CDK2-Hemmer; BG-C9074, ein Anti-B7H4-ADC; BGB-21447, ein Bcl-2-Hemmer; und BGB-45035, ein auf IRAK4 gerichteter CDAC. Es verfügt zudem über verschiedene präklinische Programme. Das Unternehmen unterhält Vereinbarungen mit Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical und Novartis. Das Unternehmen hieß zuvor BeiGene, Ltd. und änderte seinen Namen im Mai 2025 in BeOne Medicines AG. BeOne Medicines AG wurde 2010 gegründet und hat seinen Sitz in Basel, Schweiz.

IPO Year
2016
ISIN
US07725L1026

Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?